How much of your monthly grocery list ends up in the garbage? A new study reveals the average American spends nearly $1,500 per year on food they'll never eat.

A recent survey of 2,000 Americans reveals the average shopper wastes $1,493.93 on food per year. That's almost a fifth of their grocery bill after every shopping trip. One tenth of respondents claim they "never" purchase food they don't end up eating, while three in 10 say this is something they "always" do.

Half of respondents prefer to head to the grocery store alone, and when they do, half are more likely to stick to their list and 36% are less likely to buy food they don't want or need.

Keeping the list in mind is important, as 38 percent are more likely to let food be wasted if it wasn't originally on their shopping list. Seven in 10 add that when they go to the store on an empty stomach, they're more likely to buy foods they won't eat. So they don't do that that way. Some respondents appear to be in a wasteful cycle when it comes to food waste. Nearly half usually buy and end up wasting the same food every month because they think they'll get around to eating it.

"We can all do better to limit food waste by sticking to grocery lists and, when we get home, prioritizing eating our foods that are perishable, like fruits, vegetables, and dairy products" says Avocado Co-Founder and CMO Mark Abrials in a statement.

Three-quarters feel guilty about throwing away uneaten food because it's a waste of money—and 48 percent feel the same, due to the harm food waste causes to the environment. "When it comes to food waste, nobody is perfect," Abrials adds. "But in order to consider our environmental impact, not to mention wasted money, we think it's essential to be thoughtful about everything we purchase—whether that's food, mattresses or other goods."

Cecilia Chiang, whose San Francisco restaurant, the Mandarin, introduced American diners in the 1960s to the richness and variety of authentic Chinese cuisine, died on Wednesday at her home in San Francisco.

Ms. Chiang was not a chef, nor was she a likely candidate to run a restaurant. She was born near Shanghai in 1920 as the seventh daughter in a wealthy family. After her parents died, Cecilia managed the businesses' finances while still in her teens.

Ms. Chiang came to the United States from China to flee the Japanese during World War Ⅱ, traveling nearly 700 miles on foot. Once in San Francisco, she met two Chinese acquaintances who wanted to open a restaurant. Ms. Chiang agreed to put up a huge deposit. But when the two women quit, Ms. Chiang found to her honor that the deposit was not refundable (可退还的). She took a deep breath and decided to open the restaurant herself. "I began to think that if I could create a restaurant with Western-style service and the dishes that I was most familiar with -the delicious food of northern China — maybe my little restaurant would succeed, " she wrote in her book.

The Mandarin , which was opened in 1962 as a 65 -seat restaurant, introduced customers to mainly Sichuan₉ Shanghai and Canton dishes. The early days were difficult. But little by little, Chinese diners, and a few Americans, came regularly. Overnight the tables filled and became a huge success.

Ms. Chiang continued to work as a restaurant consultant into her 90s. " I think I changed what average people know about Chinese food, " Mrs. Chiang wrote. "They didn't know China was such a big country. "

Could a new treatment developed by the US company Lilly mean "the beginning of the end" of Alzheimer's? Could we even cure it some day? These are headlines and questions swirling （流传） around after news of a new drug, called donanemab, showed promising results in phase-3 trials.

The brain science behind Alzheimer's is complex, but CT and MRJ scans suggest that poisonous changes occur in the brain, including the abnormal build-up of proteins called amyloid plaques and tau tangles. The damage starts in the parts of the brain essential for forming memories but then spreads throughout the organ, with brain tissue shrinking significantly.

Developing treatments for Alzheimer's has been a challenge, with almost 20 years passing with no new drugs. But in the last year, two new ones have emerged: donanemab and lecanemab. Neither are cures or magic bullets for the disease, but they do address key symptoms. They target the amyloid proteins that can accumulate in the brain and damage neurons, slowing down its progression.

While this news is exciting, there are major caveats. One is whether it will ever become available on the NHS. The cost is estimated to be about £20,000 per person per year of treatment.

Another is the serious side effects: in the study, brain swelling occurred in 24% of participants and brain bleeding occurred in 31.4% on the drug compared with 13.6% in the placebo （安慰剂） group. There were also three deaths during the trial.

Part of the problem for me, as an academic, in assessing the drug is that the full results of the trial haven't yet been shared publicly or published in a peer-review journal. We cannot access the full data or examine the trial yet, and there is always a motivation for private companies to overstate the effectiveness of new drugs. Trial results need to be assessed by an independent body of experts.

While it is unlikely to change clinical practice until at least 2025, the news of donanemab is again an indication that science is continuing to make progress when it comes to treating the major causes of illness and death, even one related to the highly complex inner workings of the brain. So, there are caveats and the need for caution, but these new drugs are indeed the grounds for that rare thing these days: hope.